Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 14.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; App |
| 20.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tion 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoint |
| 05.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tion 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoint |
| 02.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tion 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors: Appoint |
Stammdaten
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Unternehmen & Branche
| Name | C4 Therapeutics, Inc. |
|---|---|
| Ticker | CCCC |
| CIK | 0001662579 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 226,5 Mio. USD |
| Beta | 2,86 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 35,947,000 | -104,994,000 | -1.27 | 359,075,000 | 256,587,000 |
| 2025-09-30 | 10-Q | 11,230,000 | -32,166,000 | -0.44 | 265,488,000 | 154,408,000 |
| 2025-06-30 | 10-Q | 6,463,000 | -26,020,000 | -0.37 | 296,527,000 | 174,064,000 |
| 2025-03-31 | 10-Q | 7,238,000 | -26,322,000 | -0.37 | 319,524,000 | 195,140,000 |
| 2024-12-31 | 10-K | 35,584,000 | -105,316,000 | -1.52 | 349,602,000 | 215,986,000 |
| 2024-09-30 | 10-Q | 15,362,000 | -24,666,000 | -0.35 | 376,060,000 | 242,656,000 |
| 2024-06-30 | 10-Q | 12,006,000 | -17,716,000 | -0.26 | 381,093,000 | 247,058,000 |
| 2024-03-31 | 10-Q | 3,039,000 | -28,361,000 | -0.41 | 398,371,000 | 258,282,000 |
| 2023-12-31 | 10-K | 20,756,000 | -132,493,000 | -2.67 | 376,451,000 | 246,114,000 |
| 2023-09-30 | 10-Q | 11,072,000 | -27,037,000 | -0.55 | 333,013,000 | 216,024,000 |
| 2023-06-30 | 10-Q | 2,664,000 | -35,922,000 | -0.73 | 375,008,000 | 233,707,000 |
| 2023-03-31 | 10-Q | 3,759,000 | -34,780,000 | -0.71 | 396,036,000 | 262,470,000 |
| 2022-12-31 | 10-K | 31,096,000 | -128,175,000 | -2.62 | 430,840,000 | 289,234,000 |
| 2022-09-30 | 10-Q | 6,754,000 | -31,958,000 | -0.65 | 461,439,000 | 318,179,000 |
| 2022-06-30 | 10-Q | 13,834,000 | -27,412,000 | -0.56 | 492,475,000 | 344,593,000 |
| 2022-03-31 | 10-Q | 7,654,000 | -31,620,000 | -0.65 | 515,485,000 | 364,529,000 |
| 2021-12-31 | 10-K | 45,785,000 | -83,892,000 | -1.82 | 506,765,000 | 389,606,000 |
| 2021-09-30 | 10-Q | 8,500,000 | -24,683,000 | -0.51 | 507,911,000 | 398,780,000 |
| 2021-06-30 | 10-Q | 9,781,000 | -22,580,000 | -0.51 | 528,421,000 | 416,427,000 |
| 2021-03-31 | 10-Q | -20,971,000 | 374,007,000 | 263,705,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.